Rome Therapeutics advances dark genome drug after completing $72M Series B extension backed by Big Pharma

Ayisha Sharma

News Reporter

Dark genome-focused biotech Rome Therapeutics has completed an oversubscribed $72 million Series B extension supported by new Big Pharma backers, with an eye to advancing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Rome Therapeutics advances dark genome drug after completing $72M Series B extension backed by Big Pharma

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B

AbbVie doubles down on siRNA with $335M upfront bet on ADARx

Advocacy groups and experts call for decade-long ban on germline editing

SK, Carlyle bolster bluebird bio bid; Therini Bio raises $39M

Lack of detail in Trump's drug price plan raises more questions than answers

Rome Ther­a­peu­tics ad­vances dark genome drug af­ter com­plet­ing $72M Se­ries B ex­ten­sion backed by Big Phar­ma

News Reporter

Sign up to read this article for free.

more like this

ImmunityBio, Inc.

Remote

Rome Therapeutics advances dark genome drug after completing $72M Series B extension backed by Big Pharma